Topical tofacitinib for atopic dermatitis: a phase II a randomized trial
British Journal of Dermatology2016Vol. 175(5), pp. 902–911
Citations Over TimeTop 1% of 2016 papers
Robert Bissonnette, Kim Papp, Yves Poulin, Melinda Gooderham, Maitreyi Raman, Lotus Mallbris, C. Wang, Vivek S. Purohit, Carla Mamolo, Jocelyne Papacharalambous, W.C. Ports
Abstract
Tofacitinib ointment showed significantly greater efficacy vs. vehicle across end points, with early onset of effect and comparable safety/local tolerability to vehicle. JAK inhibition through topical delivery is potentially a promising therapeutic target for AD.
Related Papers
- → Tofacitinib, an oral Janus kinase inhibitor, in patients from Brazil with rheumatoid arthritis(2018)13 cited
- Tofacitinib (cp-690,550), an oral Janus Kinase Inhibitor: Pooled phase 3 analysis in an Australian Rheumatoid Arthritis Study Population(2012)
- → Tofacitinib, an oral Janus kinase inhibitor, in patients from Colombia with rheumatoid arthritis: Pooled efficacy and safety analyses of data from phase III studies(2018)3 cited
- → Long-term safety data for tofacitinib, an oral Janus kinase inhibitor, for the treatment for psoriasis(2018)5 cited
- → THU0193 Reestablishment of efficacy of tofacitinib, an oral janus kinase inhibitor, in rheumatoid arthritis patients after temporary discontinuation(2017)2 cited